Literature DB >> 7568160

Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation.

N Schormann1, J R Murrell, J J Liepnieks, M D Benson.   

Abstract

An immunoglobulin light chain protein was isolated from the urine of an individual (BRE) with systemic amyloidosis. Complete amino acid sequence of the variable region of the light chain (VL) protein established it as a kappa I, which when compared with other kappa I amyloid associated proteins had unique residues, including Ile-34, Leu-40, and Tyr-71. To study the tertiary structure, BRE VL was expressed in Escherichia coli by using a PCR product amplified from the patient BRE's bone marrow DNA. The PCR product was ligated into pCZ11, a thermal-inducible replication vector. Recombinant BRE VL was isolated, purified to homogeneity, and crystallized by using ammonium sulfate as the precipitant. Two crystal forms were obtained. In crystal form I the BRE VL kappa domain crystallizes as a dimer with unit cell constants isomorphous to previously published kappa protein structures. Comparison with a nonamyloid VL kappa domain from patient REI, identified significant differences in position of residues in the hypervariable segments plus variations in framework region (FR) segments 40-46 (FR2) and 66-67 (FR3). In addition, positional differences can be seen along the two types of local diads, corresponding to the monomer-monomer and dimer-dimer interfaces. From the packing diagram, a model for the amyloid light chain (AL) fibril is proposed based on a pseudohexagonal spiral structure with a rise of approximately the width of two dimers per 360 degree turn. This spiral structure could be consistent with the dimensions of amyloid fibrils as determined by electron microscopy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7568160      PMCID: PMC40827          DOI: 10.1073/pnas.92.21.9490

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution.

Authors:  O Epp; E E Lattman; M Schiffer; R Huber; W Palm
Journal:  Biochemistry       Date:  1975-11-04       Impact factor: 3.162

2.  Raster3D Version 2.0. A program for photorealistic molecular graphics.

Authors:  E A Merritt; M E Murphy
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1994-11-01

3.  Improved methods for building protein models in electron density maps and the location of errors in these models.

Authors:  T A Jones; J Y Zou; S W Cowan; M Kjeldgaard
Journal:  Acta Crystallogr A       Date:  1991-03-01       Impact factor: 2.290

4.  Production and functional analysis of normal and variant recombinant human transthyretin proteins.

Authors:  J R Murrell; R G Schoner; J J Liepnieks; H N Rosen; A C Moses; M D Benson
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

5.  DNA banking: the effects of storage of blood and isolated DNA on the integrity of DNA.

Authors:  L Madisen; D I Hoar; C D Holroyd; M Crisp; M E Hodes
Journal:  Am J Med Genet       Date:  1987-06

6.  The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution.

Authors:  J A Hamilton; L K Steinrauf; B C Braden; J Liepnieks; M D Benson; G Holmgren; O Sandgren; L Steen
Journal:  J Biol Chem       Date:  1993-02-05       Impact factor: 5.157

7.  Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features.

Authors:  W Kabsch; C Sander
Journal:  Biopolymers       Date:  1983-12       Impact factor: 2.505

8.  Crystal and molecular structure of the dimer of variable domains of the Bence-Jones protein ROY.

Authors:  P M Colman; H J Schramm; J M Guss
Journal:  J Mol Biol       Date:  1977-10-15       Impact factor: 5.469

9.  Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.

Authors:  W Colon; J W Kelly
Journal:  Biochemistry       Date:  1992-09-15       Impact factor: 3.162

10.  Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda).

Authors:  A Solomon; B Frangione; E C Franklin
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

View more
  18 in total

1.  Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains.

Authors:  R Raffen; L J Dieckman; M Szpunar; C Wunschl; P R Pokkuluri; P Dave; P Wilkins Stevens; X Cai; M Schiffer; F J Stevens
Journal:  Protein Sci       Date:  1999-03       Impact factor: 6.725

2.  Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).

Authors:  Roshini S Abraham; Susan M Geyer; Marina Ramírez-Alvarado; Tammy L Price-Troska; Morie A Gertz; Rafael Fonseca
Journal:  J Clin Immunol       Date:  2004-07       Impact factor: 8.317

3.  Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains.

Authors:  Lawreen H Connors; Yan Jiang; Marianna Budnik; Roger Théberge; Tatiana Prokaeva; Kip L Bodi; David C Seldin; Catherine E Costello; Martha Skinner
Journal:  Biochemistry       Date:  2007-11-16       Impact factor: 3.162

4.  Altered dimer interface decreases stability in an amyloidogenic protein.

Authors:  Elizabeth M Baden; Barbara A L Owen; Francis C Peterson; Brian F Volkman; Marina Ramirez-Alvarado; James R Thompson
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

5.  Structural insights into the role of mutations in amyloidogenesis.

Authors:  Elizabeth M Baden; Edward G Randles; Awo K Aboagye; James R Thompson; Marina Ramirez-Alvarado
Journal:  J Biol Chem       Date:  2008-09-02       Impact factor: 5.157

6.  Effect of single point mutations in a form of systemic amyloidosis.

Authors:  Manikanthan Bhavaraju; Ulrich H E Hansmann
Journal:  Protein Sci       Date:  2015-07-14       Impact factor: 6.725

7.  Using empirical phase diagrams to understand the role of intramolecular dynamics in immunoglobulin G stability.

Authors:  Joshua D Ramsey; Michelle L Gill; Tim J Kamerzell; E Shane Price; Sangeeta B Joshi; Steven M Bishop; Cynthia N Oliver; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534

Review 8.  Amyloid formation in light chain amyloidosis.

Authors:  Marina Ramirez-Alvarado
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

9.  Light chain amyloidosis - current findings and future prospects.

Authors:  Elizabeth M Baden; Laura A Sikkink; Marina Ramirez-Alvarado
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

Review 10.  Primary systemic amyloidosis.

Authors:  R L Comenzo
Journal:  Curr Treat Options Oncol       Date:  2000-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.